The most authoritative evidence review in medicine has finally confirmed what millions of men and their families have suspected: routine screening for prostate cancer saves lives — and targeted testing could save thousands more every year.
A Cochrane review covering nearly 800,000 men across six countries has reversed two decades of doubt about PSA testing. Here is what it means for you.
From genetic risk scores to MRI-guided biopsies, the science of finding prostate cancer early has never been more advanced. So why are most men still not being screened?
Every fourteen minutes, somewhere in the world, a man dies of prostate cancer. That is more than 1,000 deaths every single day — a toll that amounts to roughly 397,000 lives lost globally each year, according to the most recent GLOBOCAN estimates. And yet, for decades, the medical establishment was unable to say with any confidence that routine testing could prevent those deaths. That uncertainty has now shifted dramatically, with the publication of a sweeping new review that carries enormous implications for men, their families, and health systems around the world.
The Cochrane Collaboration, a globally respected independent research network whose systematic reviews are considered the gold standard of evidence-based medicine, has published its most comprehensive assessment yet of prostate-specific antigen (PSA) screening. The conclusion, which marks a historic reversal of the group's own previous findings from 2006 and 2013, is that PSA blood testing "likely reduces the risk of dying" from prostate cancer. For a field mired in controversy for over a generation, that statement is nothing short of a turning point.
The review, published in May 2026, analysed data from six major trials involving close to 800,000 participants across Europe and North America. Its lead author, Dr Juan Franco of Heinrich Heine University Düsseldorf, said researchers now have "moderate certainty" that screening leads to a real reduction in disease-specific deaths. The numbers tell a clear story: PSA screening reduced prostate cancer deaths by approximately two men for every 1,000 screened. Currently, without any screening, around 16 in every 1,000 men die from the disease; routine testing could bring that figure down to 14. For every 500 men invited to be screened, one life is saved.
To some, that might sound modest. But scale it up across populations of tens of millions, and the arithmetic becomes profound. Dr Phillip Dahm, a urologist at the University of Minnesota and senior author of the review, did not mince words: "The main finding of our review is that we can now say for the first time with authority that prostate cancer screening does reduce prostate cancer mortality." He added that there is now "a reasonable evidence base to support a conversation about PSA screening" in policy settings that have previously resisted it.
The weight of those words is difficult to overstate. For years, the debate around PSA testing has been paralysed by its known limitations — high rates of false positives, overdiagnosis of slow-growing tumours that might never cause harm, and the distress and side effects that follow unnecessary biopsies and treatment. Those concerns remain valid, and no serious researcher is calling for indiscriminate mass screening of every adult male. But the new review draws a sharper distinction between blanket testing and intelligently targeted testing — and it is the latter that advocates say could save thousands of lives without causing more harm than good.
The Cochrane findings did not emerge in isolation. They are powerfully reinforced by a separate landmark study published in the New England Journal of Medicine, which tracked the outcomes of men enrolled in the European Randomized Study of Screening for Prostate Cancer (ERSPC) over an extraordinary 23-year follow-up period. That study, conducted by Professor Monique J. Roobol and her team at Erasmus MC Cancer Institute in Rotterdam, found that men who were offered PSA screening were 13% less likely to die from prostate cancer than those who were not screened. Crucially, the longer researchers followed the men, the stronger the benefit became — a finding that suggests the true scale of benefit from early detection takes many years to emerge fully, which may explain why shorter studies previously failed to detect it.
The ERSPC data also showed meaningful improvements in the efficiency of screening itself. Where earlier analyses found that 628 men needed to be invited for screening to prevent one prostate cancer death, the 23-year data reduced that number to 456 men — and only 12 diagnoses were needed to prevent a single death, compared with 18 in earlier results. "These long-term results show that PSA screening saves lives," said Professor Roobol. The improving ratio of benefit to harm over time makes the case for structured, sustained screening programmes far stronger than it was even five years ago.
To understand why this matters so urgently, consider the scale of the problem. Prostate cancer is the fourth most common cancer worldwide and the second most common cancer in men, with approximately 1.47 million new cases diagnosed globally in 2022 alone. In nearly two-thirds of all countries, it is the most frequently diagnosed tumour among men. In the United States, one in every eight men will develop prostate cancer during his lifetime, with an estimated 313,780 new cases projected for 2025. The lifetime risk climbs dramatically with age, from just 0.2% before 50 to 6.5% in men aged 70 to 79.
The global picture looks even more alarming when projected forward. The Commission on Prostate Cancer predicts that global incidence will double to around 2.9 million cases by 2040, and mortality will increase by 85%. That trajectory, driven by ageing populations and rising rates in countries previously considered low-risk, makes the case for effective early-detection strategies not merely important — but urgent. A disease that kills close to 712,000 men annually by 2040 if current trends continue is not one that health systems can afford to leave unscreened.
The human geography of prostate cancer is also deeply unequal. The African region reports the highest prostate cancer mortality worldwide, while five-year survival rates exceed 90% in high-income countries but fall to just 28% in South Africa. In the United Kingdom, where approximately 55,000 new cases are diagnosed and 12,000 men die from the disease every year, Black men face a disproportionately higher lifetime risk than white men — a risk that cuts across socioeconomic lines and is not adequately addressed by the current opportunistic testing system. The same pattern holds in the United States, where Black men are significantly more likely to be diagnosed at a later stage and to die from the disease than their white counterparts.
It is against this backdrop that the United Kingdom's National Screening Committee made headlines in November 2025, when it published a draft recommendation that men aged 45 to 61 who carry confirmed BRCA1 or BRCA2 gene variants should be offered targeted PSA screening every two years. This was a significant step — the first formal move towards any kind of structured prostate cancer screening programme in the UK — but it disappointed cancer charities and many clinicians, who had hoped for a broader programme covering all men at elevated risk, including Black men and those with a family history of the disease.
Prostate Cancer UK responded by calling the decision "a missed opportunity," noting that prostate cancer remains the only major cancer in the UK without a mass screening programme. Amy Rylance, the charity's Director of Health Services, Equity and Improvement, said: "Many of us were deeply disappointed by the committee's decision to recommend screening only for men with BRCA gene variations. That's why we're so focused on closing the critical evidence gaps, so that the men at highest risk — Black men and those with a family history of the disease — aren't being left behind." The charity's groundbreaking TRANSFORM trial, now underway, is specifically designed to generate the evidence needed to support a much wider programme.
The BRCA gene connection is itself a story of evolving understanding. Men with pathogenic BRCA1 or BRCA2 gene variants carry a substantially higher lifetime risk of developing aggressive prostate cancer, and the evidence for offering them earlier and more frequent PSA testing is now strong enough that the UK's National Screening Committee has concluded it justifies a formal programme. But the BRCA variants together affect only around 1 in every 300 men — a small fraction of the total male population at elevated risk. Campaigners argue that restricting formal screening to this group while leaving other high-risk men without a systematic offer is scientifically inconsistent and ethically difficult to justify.
Professor Simpa Salami of the University of Michigan, reflecting on the broader significance of the new Cochrane review, put the challenge concisely: "This study is timely because it provides sufficient evidence to support that screening could be beneficial if it is offered appropriately to those who are most likely to benefit, and it could actually save lives." That phrase — offered appropriately — is where the most important scientific and policy work is now being done. The question is no longer whether screening works. It is how to make it work smarter.
One of the most exciting frontiers is the use of polygenic risk scores, which assess a man's inherited genetic risk of developing prostate cancer by analysing hundreds of common variants across his DNA. The landmark BARCODE1 trial, published in the New England Journal of Medicine, was the first population-based study to use a saliva-derived polygenic risk score — drawing on 130 genetic variants — to identify men at higher risk and direct them to targeted MRI-guided screening, regardless of their PSA level. Of 6,393 men whose risk scores were calculated, 745 (11.7%) scored in the top tenth percentile and were invited for further testing. Prostate cancer was detected in 40% of those who were screened, with 55.1% of those cancers classified as intermediate- or high-risk disease requiring treatment. Even more striking, 70.9% of those treatment-requiring cancers would not have been detected using the standard UK diagnostic pathway, which relies on symptomatic presentation and opportunistic PSA testing.
The implications are considerable. A saliva swab — cheap, non-invasive, and scaleable — could one day sit alongside or ahead of the PSA blood test as the entry point to a more intelligent screening pathway. A 2025 study published in Nature Medicine demonstrated that combining polygenic risk scores with AI-analysed MRI features boosted the accuracy of detecting clinically significant prostate cancer to an AUC of 0.92 — a level of diagnostic precision that conventional PSA testing simply cannot match on its own, where the comparative AUC is around 0.67. This kind of multi-modal, risk-stratified approach — saliva test to identify high-risk men, then PSA and MRI for those flagged, then targeted biopsy only where truly warranted — is precisely the direction that leading researchers believe will resolve the long-standing tension between the benefits and harms of screening.
MRI itself has already transformed the screening landscape in ways that were not fully reflected in the older trial data that fed previous Cochrane reviews. Modern multiparametric MRI, when used before biopsy in men with elevated PSA, has significantly reduced the detection of clinically insignificant prostate cancers — the slow-growing tumours that are diagnosed but never cause harm — while maintaining excellent detection of aggressive disease. The use of MRI has also dramatically reduced complications from biopsies. Where traditional transrectal biopsies carried a meaningful risk of serious infection, newer transperineal biopsy techniques guided by MRI imaging are far safer and more precise. These advances directly address the historical harms argument against screening, which was partly built on biopsy complication rates that modern clinical practice has substantially reduced.
A systematic review of 16 studies published between 2014 and 2024 found that PSA screening reduced prostate-cancer-specific mortality by between 20 and 31% in men aged 55 to 69, drawing on data from randomised controlled trials including ERSPC and the Finnish ProScreen study. That range of benefit is not trivial — it represents, in absolute population terms, thousands of preventable deaths each year if screening is deployed correctly. The same review noted that potential harms, including overdiagnosis and psychological distress, remain real considerations, but concluded that modern tools — MRI, multi-biomarker panels, and refined risk stratification — have improved the benefit-harm balance considerably compared with the era in which the earlier negative Cochrane verdicts were formed.
The Cochrane review was also notable for something it did not find: unlike earlier analyses, it did not detect an increase in the likelihood of negative side effects from biopsies or prostate cancer treatment in the screened groups compared to the unscreened groups. That finding softens one of the major objections to expanding PSA testing — that the cascade of harms from follow-up procedures could outweigh the lives saved. The authors are careful to emphasise that their findings support intelligent, consent-based screening rather than compulsory mass testing, but the direction of travel in the evidence is clear.
Oliver Kemp, Chief Executive of Prostate Cancer Research UK, welcomed the Cochrane review as marking "an important moment in the prostate cancer screening debate." Former UK Prime Minister Rishi Sunak, who has been among the most prominent political voices calling for a national prostate cancer screening programme, said: "As this important research shows, a targeted national screening programme for prostate cancer would save lives. The Daily Mail is right that we must prevent more families from losing a father, a brother or a son to this cruel disease." That public and political pressure, now backed by increasingly robust science, is making it harder for health authorities to maintain the status quo.
What does all of this mean in practice for men, today? In the UK, every man over 50 who has considered the advantages and disadvantages of the PSA blood test can request one from his GP, without needing to have symptoms. In the United States, guidelines from major oncology bodies now support shared decision-making discussions about PSA testing from age 50 for average-risk men, from 45 for Black men and those with a first-degree relative diagnosed with prostate cancer, and from 40 for men with more than one first-degree relative affected at an early age. Across Europe, many countries are already moving towards more structured, risk-stratified approaches informed by the ERSPC data and the BARCODE1 genetic screening model.
The challenge is ensuring that this shift reaches men who have historically been least well served by prostate cancer pathways. Research consistently shows that Black men and men in more deprived areas remain far more likely to be diagnosed late and to die from prostate cancer than men from more privileged backgrounds — a disparity that cannot be corrected by policies that restrict formal screening to the BRCA-positive minority. Addressing health inequality in prostate cancer means ensuring that awareness, access, and testing reach all men at elevated risk, regardless of postcode, ethnicity, or family connections to genetic testing services.
There is also the question of what to do with a positive test. The era of reflexively treating every prostate cancer diagnosis with surgery or radiotherapy is thankfully receding. For men diagnosed with low-risk, slow-growing tumours, active surveillance — watchful monitoring without immediate treatment — is now established practice in clinical guidelines across the UK, US, Europe, and Australia. The goal of a well-designed screening programme is not to diagnose every prostate cancer, but to find the cancers that will kill men before those cancers have had the chance to spread beyond the prostate gland, where treatment is curative rather than merely life-extending. When screening is paired with modern diagnostic tools and nuanced treatment decisions, the old picture of mass overtreatment can be replaced by something genuinely beneficial.
The story of prostate cancer screening has, for too long, been a story of uncertainty, controversy, and missed opportunity. Men have died waiting for the science to catch up with common sense. Now, in the convergence of the new Cochrane review, the 23-year ERSPC data, the BARCODE1 polygenic screening results, and the rapid evolution of MRI-guided diagnosis, the science has caught up. The next step — and it cannot come soon enough — is for health systems to act on it.
For more information on prostate cancer risk and testing, visit Prostate Cancer UK, ZERO Prostate Cancer, or the World Cancer Research Fund for global statistics and guidance.
0 Comments